(Q34136065)

31 July 2017

title

Thrombohemorrhagic complications of myeloproliferative disorders (English)

1 reference

31 July 2017

3

Benjamin Brenner

1 reference

31 July 2017

Emmanouil Papadakis

1

1 reference

31 July 2017

Ron Hoffman

2

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20817333

6 July 2024

publication date

1 November 2010

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S0268960X1000041X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

https://api.elsevier.com/content/article/PII:S0268960X1000041X?httpAccept=text/plain

6 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

6 July 2024

1 reference

31 July 2017

volume

24

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

227-232

1 reference

The chronic myeloproliferative disorders: clonality and clinical heterogeneity

31 July 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

6 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

6 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Cardiac involvement in patients with myeloproliferative disorders

6 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

6 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

6 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

6 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

6 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Thrombosis in primary myelofibrosis: incidence and risk factors

6 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment

6 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Clinical course of essential thrombocythemia in 147 cases

6 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients

6 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

6 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia

6 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

6 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

6 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

6 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients

6 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

6 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases

6 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years

6 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Is polycythemia vera a serious disease in young adults?

6 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

6 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis

6 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications

6 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

6 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism--thesis, Rotterdam, 1981.

6 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

6 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Erythromelalgia: review of clinical characteristics and pathophysiology

6 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia

6 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients

6 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

6 July 2024

The Budd-Chiari syndrome

37

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera

6 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia

6 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Hyperviscosity in polycythemia vera and other red cell abnormalities

6 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates

6 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Red blood cells: their dual role in thrombus formation

6 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

The red blood cell in vascular occlusion

6 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery

6 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

6 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases

6 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

6 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count

6 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count

6 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Collagen Binding Assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and Discrimination of VWD Subtypes, Depends on Collagen Source

6 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Platelet Hyperaggregability and Thrombosis in Patients with Thrombocythemia

6 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo

6 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders

6 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

6 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

6 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

6 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

6 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

6 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

A gain-of-function mutation of JAK2 in myeloproliferative disorders

6 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Identification of an acquired JAK2 mutation in polycythemia vera

6 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation

6 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

6 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide

6 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera

6 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

6 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

6 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

6 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease

6 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Efficacy and safety of low-dose aspirin in polycythemia vera

6 July 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Polycythemia vera: a comprehensive review and clinical recommendations

6 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

6 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

6 July 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2010.08.002

6 July 2024

Identifiers

1 reference

31 July 2017

1 reference